Eric Konofal
Head of Doxa Program at Newcelx
Based in Paris, France
7-day free trial · no credit card
Seniority
Other
Department
Other
Location
Paris
Industry
Biotechnology Research
Company size
30
Contact information
Reveal Eric's email and phone
Direct contact data is gated. Sign up and reveal. You only pay for verified records.
e•••••••@newcelx.com
Phone
5 credits+33 ••• •••• ••••
You only pay for valid records. Bounced emails and disconnected numbers cost nothing.
Background
About Eric Konofal
Eric Konofal, MD, PhD, is a senior medical consultant at the Paediatric Sleep Disorders Center and clinical investigator (CIC 9202), at Clinical Pharmacology & Pharmacogenetic Department of Robert Debré Hospital (APHP). Dr. Konofal is a nationally and internationally recognized as a sleep disorder researcher, scientist, and medical investigator in ADHD, RLS, and Alertness and Wake-Deficit Spectrum Disorders. His research interests are also focused on brain- and iron-dopamine interactions in subjects with neurological sleep disorders. He has still initiated previous studies based on iron and its interest in pathophysiology of ADHD and has explored the relationship between brain and iron. He has launched a clinical trial on efficiency of mazindol in children with ADHD (clinicaltrials.gov identifier: NCT00508677).Patents/PCT:WO/2004/105744, (2004-)WO/2007/116076 (2007-)WO 2012/09823http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012098235WO2013079873http://patentscope.wipo.int/search/en/WO2013079873Dr. Konofal is also Member of ADHD Scientific Committee of French ADHD Parents association Member of International Restless Legs Syndrome Study Group Committee, Member of European Guidelines for ADHD (EUNETHYDIS), Expert for the French National Administration of Health (AFSSAPS) and Expert Consultant for European Agency EMA (PIP). Dr. Konofal has created a first BioTech (BLK Pharma), which has been incubated at Paris BioTech Santé Paris (2010-2013) and has been co-founder of NeuroLifeSciences (NLS), which is formally involved in Wake-Deficit Spectrum Disorders for Drugs Development and Research.These drugs are respectively potent in: Decline of alertness (in elderly); Alertness; Physical Stimulation and Vigilance.
Decision-makers
Other people at Newcelx
Build a list of verified contacts at Newcelx
Free for 7 days · 50 credits · no card · only pay for verified records.
Reach more buyers like Eric
250M+ professionals with verified email and phone. You only pay for records that actually verify.
7-day trial · no credit card · cancel anytime